Cedar

Curative is shifting from COVID-19 testing to launching a new health plan as testing needs decrease.

In a post on LinkedIn, CEO and cofounder Florian Otto said the cuts will allow the company to "adapt to current market realities, and re-organize ourselves for what we want to achieve following last year's acquisition of OODA Health."

Also: Zipari rounds out its C-suite with two appointments.   

The companies hope they can alleviate some of the problems that lead to poor consumer financial experiences and administrative waste in healthcare.   

Also: Valo Health closes $300 million for machine learning drug discovery; Blue Note Therapeutics supports its in-development prescription DTx with $26.25 million.

The new round led by Andreessen Horowitz will be put towards expanding the company's growth. 

High deductibles and increased engagement are changing what patients expect out of their insurer and provider.